X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of the PPARγ.
Lead Product(s): NAC-GED-0507
Therapeutic Area: Dermatology Product Name: NAC-GED-0507
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Nogra Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2023
Details:
VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Verrica Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BioCryst Pharmaceuticals
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 14, 2021
Details:
Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Verrica Pharmaceuticals
Deal Size: $69.5 million Upfront Cash: $11.5 million
Deal Type: Licensing Agreement March 17, 2021
Details:
The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Verrica Pharmaceuticals
Deal Size: $70.0 million Upfront Cash: $11.5 million
Deal Type: Agreement August 05, 2020
Details:
Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: BioCryst Pharmaceuticals
Deal Size: $42.0 million Upfront Cash: $22.0 million
Deal Type: Agreement February 03, 2020
Details:
Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Japan Tobacco Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
